Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

Stimvia-Parkinsons

More Like This

PR Newswire associated0

TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S CELL THERAPY PROGRAM AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

PR Newswire associated0

UroMems Reaches Significant Milestone: Successful Results in Clinical Feasibility Study of UroActive™ Smart Implant for Stress Urinary Incontinence Treatment

PR Newswire associated0

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

PR Newswire associated0

TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON

TreeFrog Therapeutics 10L bioreactor for cell therapy (Photo credits: TreeFrog Therapeutics)

TreeFrog Publishes Results of First Successful Bioproduction of a Parkinson’s Disease Cell Therapy in Scalable Bioreactor in Neurotherapeutics Journal

PR Newswire associated0

UroMems Raises Record $47 million (€44 Million) in Series C Financing to Fund Pivotal Clinical Trials of the UroActive™ System, the First Smart Automated Implant to Treat Stress Urinary Incontinence

PR Newswire associated0

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

PR Newswire associated0

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)